Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

proSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors

NCT05221372 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT05221372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05221372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
proSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors
Lead sponsor
Erasmus Medical Center
Phase
Observational
Overall status
Recruiting
Start date
February 2, 2017
Completion date
January 1, 2031
Enrollment
1,300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liquid biopsy, non small cell lung cancer, tyrosine kinase inhibitor